Organization
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
4 abstracts
Abstract
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.Org: Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China, Department of Oncology, Jilin Cancer Hospital, Changchun, China, Linyi Cancer Hospital, Linyi, China, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China,
Abstract
Analysis of short-term efficacy and safety of mitoxantrone hydrochloride liposome regimen therapy in adult acute myeloid leukemia.Org: Department of Hematology & Oncology, College of Medicine, University of Oklahoma Health Sciences Center, Harbin Institute of Hematology & Oncology, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Tangdu Hospital, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Abstract
Fruquintinib plus sintilimab in patients with either treatment-naive or previously first line treated metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multicenter, single-arm phase 2 study.Org: Fudan University Shanghai Cancer Center, Tianjin Medical University Cancer Hospital, Peking University First Hospital, Chongqing University Cancer Hospital, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China,
Abstract
A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice.Org: Tongji University Shanghai East Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Zhejiang Cancer Hospital, Chinese Academy of Sciences,